Switch theme
Sign up to access all valuation multiples
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
2021
204
LTM Revenue $0.1M
LTM EBITDA -$175M
-$232M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ProKidney has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$175M.
In the most recent fiscal year, ProKidney achieved revenue of $0.1M and an EBITDA of -$158M.
ProKidney expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ProKidney valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$175M | XXX | -$158M | XXX | XXX | XXX |
| EBITDA Margin | -211407% | XXX | -208542% | XXX | XXX | XXX |
| EBIT | -$182M | XXX | -$184M | XXX | XXX | XXX |
| EBIT Margin | -220860% | XXX | -241679% | XXX | XXX | XXX |
| Net Profit | -$92.7M | XXX | -$61.2M | XXX | XXX | XXX |
| Net Margin | -112165% | XXX | -80508% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ProKidney's stock price is $1.
ProKidney has current market cap of $93.6M, and EV of -$232M.
See ProKidney trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$232M | $93.6M | XXX | XXX | XXX | XXX | $-0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ProKidney has market cap of $93.6M and EV of -$232M.
ProKidney's trades at -3046.1x EV/Revenue multiple, and 1.5x EV/EBITDA.
Equity research analysts estimate ProKidney's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ProKidney has a P/E ratio of -1.0x.
See valuation multiples for ProKidney and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $93.6M | XXX | $93.6M | XXX | XXX | XXX |
| EV (current) | -$232M | XXX | -$232M | XXX | XXX | XXX |
| EV/Revenue | -2802.0x | XXX | -3046.1x | XXX | XXX | XXX |
| EV/EBITDA | 1.3x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBIT | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/Gross Profit | -2802.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | 1.9x | XXX | 1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProKidney's last 12 month revenue growth is -35%
ProKidney's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.9M for the same period.
ProKidney's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ProKidney's rule of X is -211494% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ProKidney and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -211407% | XXX | -208542% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -208577% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -211494% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 167984% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 241779% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ProKidney acquired XXX companies to date.
Last acquisition by ProKidney was XXXXXXXX, XXXXX XXXXX XXXXXX . ProKidney acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ProKidney founded? | ProKidney was founded in 2021. |
| Where is ProKidney headquartered? | ProKidney is headquartered in United States of America. |
| How many employees does ProKidney have? | As of today, ProKidney has 204 employees. |
| Who is the CEO of ProKidney? | ProKidney's CEO is Dr. Bruce Culleton, M.D.. |
| Is ProKidney publicy listed? | Yes, ProKidney is a public company listed on NAS. |
| What is the stock symbol of ProKidney? | ProKidney trades under PROK ticker. |
| When did ProKidney go public? | ProKidney went public in 2022. |
| Who are competitors of ProKidney? | Similar companies to ProKidney include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ProKidney? | ProKidney's current market cap is $93.6M |
| What is the current revenue of ProKidney? | ProKidney's last 12 months revenue is $0.1M. |
| What is the current revenue growth of ProKidney? | ProKidney revenue growth (NTM/LTM) is -35%. |
| What is the current EV/Revenue multiple of ProKidney? | Current revenue multiple of ProKidney is -2802.0x. |
| Is ProKidney profitable? | Yes, ProKidney is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ProKidney? | ProKidney's last 12 months EBITDA is -$175M. |
| What is ProKidney's EBITDA margin? | ProKidney's last 12 months EBITDA margin is -211407%. |
| What is the current EV/EBITDA multiple of ProKidney? | Current EBITDA multiple of ProKidney is 1.3x. |
| What is the current FCF of ProKidney? | ProKidney's last 12 months FCF is -$122M. |
| What is ProKidney's FCF margin? | ProKidney's last 12 months FCF margin is -148004%. |
| What is the current EV/FCF multiple of ProKidney? | Current FCF multiple of ProKidney is 1.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
